Global Solid Organ Transplantation Market, By Organ (Kidney, Liver, Pancreas, Heart, Lung, Small Bowel, Kidney/Pancreas, Others), Product (Tissue Products, Immunosuppressive Drugs, Preservation Solution), Treatment (Immunosuppressive, Monoclonal Antibodies, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Solid Organ Transplantation Market Analysis and Size
The global solid organ transplantation market is expected to witness significant growth during the forecast period. Increasing demand for novel tissue transplantation products and organ transplantation for the treatment of organ failure is a foremost factor leading to the market growth. Unhealthy dietary habits, lack of exercise, alcohol consumption, and drug abuse are some important causes of organ failure. It has been witnessed that tissue products were the highest revenue-generating segment in 2021 having a market share of 57.8%. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global solid organ transplantation market in the forecast period 2022-2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Solid organ transplantation works like an advantage for patients suffering from end-stage kidney, pancreas, small intestine, heart, liver, and lung diseases. Although, it is not a process that improves survival, certain quality-of-life improvements are realized with vascular composite allograft and uterus transplantation. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Solid Organ Transplantation Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Organ (Kidney, Liver, Pancreas, Heart, Lung, Small Bowel, Kidney/Pancreas, Others), Product (Tissue Products, Immunosuppressive Drugs, Preservation Solution), Treatment (Immunosuppressive, Monoclonal Antibodies, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Teva Pharmaceutical Industries Ltd (Israel), Mylan N.V (U.S.), Johnsons & Johnsons Services Inc (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), Lilly (U.S.), Merck & Co., Inc. (U.S.), Aurobindo Pharma (India), Bristol-Myers Squibb Company (U.S.), GSK plc (U.K.), Ascendis Pharma A/S (Denmark), LEO Pharma A/S (Denmark), Genentech, Inc (U.S.), Celltrion Inc (South Korea) |
|
Market Opportunities |
|
Global Solid Organ Transplantation Market Dynamics
Drivers
- Growing Demand for Organ Transplant
The global rise in the organ transplant demand can be attributed to an increase in the occurrence of acute diseases, which in turn leads to an increase in the number of organ failures. For instance, diabetes and high blood pressure are considered to be the most common causes of end-stage renal disease, wherein kidney transplants or dialysis are the only treatment options to keep a patient alive. As per the records of the U.S. Department of Health & Human Services, about 122,913 patients in the U.S. were waiting to receive organs for transplant in 2019. Thus, the demand for advanced transplantation products for the treatment of organ failure is high.This boosts the market growth.
- Technological Advancements
Several technological advancemnets in this sector are expected to boost the growth of the market. For instance, in September 2015, Arthrex Inc. launched ArthroFlex Acellular Dermal Matrix, a new orthobiologic product proposed for use in capsular reconstruction. This product allows preservation of its growth factors and native collagen scaffold and elastin and permits transplant to be successfully incorporated into the recipient. All these factors boost the market growth.
Opportunities
- Higher Mergers and Acquisitions
Several manufacturers are aiming on new product development, mergers & acquisition, and collaborations to enlarge their current product portfolio and maintain their persistent position in the market. For instance, in September 2016, Stryker Corporation announced the acquisition of Instratek. It is a top manufacturer of minimally invasive soft tissue recession instruments for ankle, foot, and upper extremity procedures.
- Increasing Sales of Immunosuppressive Drugs
Tissue products for transplantation accounted for the largest share in 2021, and this category is projected to maintain its position in the upcoming future due to the increasing use of orthobiologics in orthopedic procedures for normal functioning restoration, tissue healing, and pain minimization, combined with the increasing elderly population across the globe. Moreover, startup companies in this field are receiving investments to expand their business. Thus, this factor is creating much opportunities for the market growth.
Restraints/Challenges
- High Cost
The huge association with organ transplantation and many other immunosuppressive drugs restrain the market growth.
- Unavailability of Treatment
Not all the treatments are available in all the countries which restrict the market growth. There are several underdeveloped countries wherein the modified treatments are not available. Thus, it restricts the growth of the market.
This global solid organ transplantation market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global solid organ transplantation market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Solid Organ Transplantation Market
There has been a significant proportion of coronavirus patients who were hospitalized in medical centers, governing bodies were bound to restrict to these patients. The pandemic also caused a drip in organ transplant surgery enrolment globally.
The reduction in the number of transplantation and organ donation procedures is mostly because of factors such as engaged surgeons, unavailability of resources, lockdown, and travel restrictions. Patients having positive reports for COVID-19 were restricted from donating organs because of the possibility of infection. Additionally, another major concern prompting transplantation operations was the possibility of immunosuppressant drug interactions with COVID-19 therapy agents, which had led to a substantial number of organ failures from graft donors.
Recent Development:
- In November 2020, Lupin launched a generic immunosuppressant drug, Tacrolimus in the U.S. market which is indicated for prophylaxis of organ rejection in the allogeneic liver, kidney, and heart transplant.
Global Solid Organ Transplantation Market Scope
The global solid organ transplantation market is segmented on the basis of organ, product, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Organ
- Kidney
- Liver
- Pancreas
- Heart
- Lung
- Small Bowel
- Kidney/Pancreas
- Others
Product
- Tissue Products
- Immunosuppressive Drugs
- Preservation Solution
Treatment
- Immunosuppressive
- Monoclonal Antibodies
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Solid Organ Transplantation Market Regional Analysis/Insights
The global solid organ transplantation market is analysed and market size insights and trends are provided by organ, product, treatment, distribution channel and end-user as referenced above.
The major countries covered in the global solid organ transplantation market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the presence of key manufacture of the product and increased healthcare and R & D expenditure.
Asia-Pacific dominates the market due to increased prevalence of organ failure, and presence of generic drugs manufacturers.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Solid Organ Transplantation Market Share Analysis
The global solid organ transplantation market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global solid organ transplantation market.
Key players operating in the global solid organ transplantation market include:
- Teva Pharmaceutical Industries Ltd (Israel)
- Mylan N.V (U.S.)
- Johnsons & Johnsons Services Inc (U.S.)
- F. Hoffman-La Roche Ltd. (Switzerland)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- Aurobindo Pharma (India)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc (U.K.)
- Ascendis Pharma A/S (Denmark)
- LEO Pharma A/S (Denmark)
- Genentech, Inc (U.S.)
- Celltrion Inc (South Korea)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL SOLID ORGAN TRANSPLANTATION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL SOLID ORGAN TRANSPLANTATION MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL SOLID ORGAN TRANSPLANTATION MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.1.1 PATENT LANDSCAPE
6.1.2 USPTO NUMBER
6.1.3 PATENT EXPIRY
6.1.4 EPIO NUMBER
6.1.5 PATENT STRENGTH AND QUALITY
6.1.6 PATENT CLAIMS
6.1.7 PATENT CITATIONS
6.1.8 PATENT LITIGATION AND LICENSING
6.1.9 FILE OF PATENT
6.1.10 PATENT RECEIVED CONTRIES
6.1.11 TECHNOLOGY BACKGROUND
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH SPECIALIST
6.8 OTHER KOL SNAPSHOTS
7 EPIDEMIOLOGY
7.1 INCIDENCE OF ALL BY GENDER
7.2 TREATMENT RATE
7.3 MORTALITY RATE
7.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
7.5 PATIENT TREATMENT SUCCESS RATES
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 REGULATORY FRAMEWORK
9.1 REGULATORY APPROVAL PROCESS
9.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
9.3 REGULATORY APPROVAL PATHWAYS
9.4 LICENSING AND REGISTRATION
9.5 POST-MARKETING SURVEILLANCE
9.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
10 PIPELINE ANALYSIS
10.1 CLINICAL TRIALS AND PHASE ANALYSIS
10.2 DRUG THERAPY PIPELINE
10.3 PHASE III CANDIDATES
10.4 PHASE II CANDIDATES
10.5 PHASE I CANDIDATES
10.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR SOLID ORGAN TRANSPLANTATION MARKET
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE SOLID ORGAN TRANSPLANTATION MARKET
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE SOLID ORGAN TRANSPLANTATION MARKET
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE SOLID ORGAN TRANSPLANTATION MARKET
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR SOLID ORGAN TRANSPLANTATION MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
11 MARKETED DRUG ANALYSIS
11.1 DRUG
11.1.1 BRAND NAME
11.1.2 GENERICS NAME
11.2 THERAPEUTIC INDICTION
11.3 PHARMACOLOGICAL CLASS OF THE DRUG
11.4 DRUG PRIMARY INDICATION
11.5 MARKET STATUS
11.6 MEDICATION TYPE
11.7 DRUG DOSAGES FORM
11.8 DOSAGES AVAILABILITY
11.9 DRUG ROUTE OF ADMINISTRATION
11.1 DOSING FREQUENCY
11.11 DRUG INSIGHT
11.12 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
11.12.1 FORECAST MARKET OUTLOOK
11.12.2 CROSS COMPETITION
11.12.3 THERAPEUTIC PORTFOLIO
11.12.4 CURRENT DEVELOPMENT SCENARIO
12 MARKET ACCESS
12.1 10-YEAR MARKET FORECAST
12.2 CLINICAL TRIAL RECENT UPDATES
12.3 ANNUAL NEW FDA APPROVED DRUGS
12.4 DRUGS MANUFACTURER AND DEALS
12.5 MAJOR DRUG UPTAKE
12.6 CURRENT TREATMENT PRACTICES
12.7 IMPACT OF UPCOMING THERAPY
13 R & D ANALYSIS
13.1 COMPARATIVE ANALYSIS
13.2 DRUG DEVELOPMENTAL LANDSCAPE
13.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
13.4 THERAPEUTIC ASSESSMENT
13.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
14 MARKET OVERVIEW
14.1 DRIVERS
14.2 RESTRAINTS
14.3 OPPORTUNITIES
14.4 CHALLENGES
15 GLOBAL SOLID ORGAN TRANSPLANTATION MARKET, BY ORGAN
15.1 OVERVIEW
15.2 KIDNEY TRANSPLANTATION
15.3 LIVER TRANSPLANTATION
15.4 HEART TRANSPLANTATION
15.5 LUNG TRANSPLANTATION
15.6 PANCREAS TRANSPLANTATION
15.7 SMALL BOWEL TRANSPLANTATION
15.8 OTHERS
16 GLOBAL SOLID ORGAN TRANSPLANTATION MARKET, BY PRODUCT
16.1 OVERVIEW
16.2 THERAPY
16.2.1 IMMUNOSUPPRESSIVE DRUGS
16.2.1.1. CALCINEURIN INHIBITORS (CNI)
16.2.1.1.1. CYCLOSPORINE
16.2.1.1.1.1 NEORAL
16.2.1.1.1.2 SANDIMMUNE
16.2.1.1.1.3 OTHERS
16.2.1.1.2. TACROLIMUS (PROGRAF)
16.2.1.1.3. OTHERS
16.2.1.2. ANTIPROLIFERATIVE AGENTS
16.2.1.2.1. AZATHIOPRINE (IMURAN)
16.2.1.2.2. MYCOPHENOLATE MOFETIL (MMF)
16.2.1.2.3. CYCLOPHOSPHAMIDE
16.2.1.2.4. LEFLUNOMIDE
16.2.1.2.5. OTHERS
16.2.1.3. MTOR INHIBITORS
16.2.1.3.1. SIROLIMUS
16.2.1.3.2. EVEROLIMUS
16.2.1.3.3. TEMSIROLIMUS
16.2.1.3.4. RIDAFOROLIMUS
16.2.1.3.5. OTHERS
16.2.1.4. CORTICOSTEROIDS
16.2.1.4.1. METHYLPREDNISOLONE
16.2.1.4.2. DEXAMETHASONE
16.2.1.4.3. PREDNISOLONE
16.2.1.4.4. OTHERS
16.2.1.5. STATIN THERAPY
16.2.1.6. ALKYLATING AGENT
16.2.1.7. INTERLEUKIN INHIBITORS
16.2.1.8. SPECIFIC LYMPHOCYTE-SIGNALING INHIBITORS
16.2.2 ANTI-DRUG ANTIBODIES
16.2.2.1. MONOCLONAL ANTIBODIES
16.2.2.1.1. MARKETED
16.2.2.1.1.1 MUROMONAB-CD3
16.2.2.1.1.2 BASILIXIMAB
16.2.2.1.1.3 BELATACEPT
16.2.2.1.1.4 ALEMTUZUMAB
16.2.2.1.1.5 OTHERS
16.2.2.1.2. INVESTIGATIONAL
16.2.2.1.2.1 ALEMTUZUMAB
16.2.2.1.2.2 RITUXIMAB
16.2.2.1.2.3 OTHERS
16.2.2.2. TNF-ALPHA INHIBITORS
16.2.2.2.1. INFLIXIMAB
16.2.2.2.2. ADALIMUMAB
16.2.2.2.3. OTHERS
16.2.2.3. OTHERS
16.2.3 THERAPEUTIC PLASMA EXCHANGE (TPE)
16.2.4 INTRAVENOUS IMMUNOGLOBULIN (IVIG)
16.3 PRESERVATION SOLUTION
16.3.1 BY SOLUTION TYPE
16.3.1.1. UW
16.3.1.2. EURO-COLLINS
16.3.1.3. BELZER'S MPS
16.3.1.4. CUSTODIOL HTK
16.3.1.5. CELSIOR
16.3.1.6. PERFADEX
16.3.1.7. POLYSOL
16.3.1.8. VIASPAN
16.3.1.9. OTHERS
16.3.2 BY METHOD OF PRESERVATION
16.3.2.1. STATIC PRESERVATION METHOD
16.3.2.2. DYNAMIC PRESERVATION METHOD
16.3.2.2.1. HYPOTHERMIC MACHINE PERFUSION PERSERVATION
16.3.2.2.2. NORMOTHERIC MACHINE PERFUSION
16.3.2.2.3. OXYGEN PERSUFFLATION
16.3.2.2.4. OTHERS
16.3.2.3. OTHERS
16.4 TISSUE PRODUCTS
16.5 OTHERS
17 GLOBAL SOLID ORGAN TRANSPLANTATION MARKET, BY ROUTE OF ADMINISTRATION
17.1 ORAL
17.1.1 TABLET
17.1.2 CAPSULE
17.1.3 OTHERS
17.2 PARENTRAL
17.2.1 INTRAVENEOUS
17.2.2 SUBCUTANEOUS
17.2.3 OTHERS
17.3 OTHERS
18 GLOBAL SOLID ORGAN TRANSPLANTATION MARKET, BY TYPE OF ORGAN DONATION
18.1 OVERVIEW
18.2 DECEASED DONOR
18.3 LIVING DONOR
19 GLOBAL SOLID ORGAN TRANSPLANTATION MARKET, BY DRUG BRAND
19.1 OVERVIEW
19.2 BRANDED
19.2.1 PROGRAF
19.2.2 CELLCEPT
19.2.3 ZORTRESS
19.2.4 RAPAMUNE
19.2.5 OTHERS
19.3 GENERICS
20 GLOBAL SOLID ORGAN TRANSPLANTATION MARKET, BY PRESCRIPTION MODE
20.1 OVERVIEW
20.2 OVER THE COUNTER (OTC)
20.3 PRESCRIPTION BASED
21 GLOBAL SOLID ORGAN TRANSPLANTATION MARKET, BY POPULATION TYPE
21.1 OVERVIEW
21.2 MALE
21.2.1 YOUNG (BELOW 30 YEARS)
21.2.2 MIDDLE AGE (30–50 YEARS)
21.2.3 ELDERLY (65 YEARS OR OLDER)
21.3 FEMALE
21.3.1 YOUNG (BELOW 30 YEARS)
21.3.2 MIDDLE AGE (30–50 YEARS)
21.3.3 ELDERLY (65 YEARS OR OLDER)
22 GLOBAL SOLID ORGAN TRANSPLANTATION MARKET, BY END USER
22.1 OVERVIEW
22.2 HOSPITAL
22.2.1 BY TYPE
22.2.1.1. PUBLIC
22.2.1.2. PRIVATE
22.2.2 BY TIER
22.2.2.1. TIER 1
22.2.2.2. TIER 2
22.2.2.3. TIER 3
22.3 SPECIALTY CLINICS
22.4 HOME HEALTHCARE
22.5 AMBULATORY SURGICAL CENTERS
22.6 ACADEMIC AND RESEARCH INSTITUTES
22.7 OTHERS
23 GLOBAL SOLID ORGAN TRANSPLANTATION MARKET, BY DISTRIBUTION CHANNEL
23.1 OVERVIEW
23.2 DIRECT TENDER
23.3 REATIL SALES
23.3.1 OFFLINE PHARMACY
23.3.1.1. HOSPITAL PHARMACY
23.3.1.2. MEDICAL STORES AND DRUGS
23.3.1.3. OTHERS
23.3.2 ONLINE PHARMACY
23.3.2.1. E-STORES
23.3.2.2. COMPANY WEBSITE
23.3.2.3. OTHERS
23.4 OTHERS
24 GLOBAL SOLID ORGAN TRANSPLANTATION MARKET, COMPANY LANDSCAPE
24.1 COMPANY SHARE ANALYSIS: GLOBAL
24.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
24.3 COMPANY SHARE ANALYSIS: EUROPE
24.4 COMPANY SHARE ANALYSIS: ASIA PACIFIC
24.5 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
24.6 MERGERS & ACQUISITIONS
24.7 NEW PRODUCT DEVELOPMENT & APPROVALS
24.8 EXPANSIONS
24.9 REGULATORY CHANGES
24.1 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
25 GLOBAL SOLID ORGAN TRANSPLANTATION MARKET, BY GEOGRAPHY
GLOBAL SOLID ORGAN TRANSPLANTATION MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
25.1 NORTH AMERICA
25.1.1 U.S.
25.1.2 CANADA
25.1.3 MEXICO
25.2 EUROPE
25.2.1 GERMANY
25.2.2 FRANCE
25.2.3 U.K.
25.2.4 HUNGARY
25.2.5 LITHUANIA
25.2.6 AUSTRIA
25.2.7 IRELAND
25.2.8 NORWAY
25.2.9 POLAND
25.2.10 ITALY
25.2.11 SPAIN
25.2.12 RUSSIA
25.2.13 TURKEY
25.2.14 NETHERLANDS
25.2.15 SWITZERLAND
25.2.16 REST OF EUROPE
25.3 ASIA-PACIFIC
25.3.1 JAPAN
25.3.2 CHINA
25.3.3 SOUTH KOREA
25.3.4 INDIA
25.3.5 AUSTRALIA
25.3.6 SINGAPORE
25.3.7 THAILAND
25.3.8 MALAYSIA
25.3.9 INDONESIA
25.3.10 PHILIPPINES
25.3.11 VIETNAM
25.3.12 REST OF ASIA-PACIFIC
25.4 SOUTH AMERICA
25.4.1 BRAZIL
25.4.2 ARGENTINA
25.4.3 PERU
25.4.4 REST OF SOUTH AMERICA
25.5 MIDDLE EAST AND AFRICA
25.5.1 SOUTH AFRICA
25.5.2 GLOBAL
25.5.3 UAE
25.5.4 EGYPT
25.5.5 KUWAIT
25.5.6 ISRAEL
25.5.7 REST OF MIDDLE EAST AND AFRICA
25.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
26 GLOBAL SOLID ORGAN TRANSPLANTATION MARKET, SWOT AND DBMR ANALYSIS
27 GLOBAL SOLID ORGAN TRANSPLANTATION MARKET, COMPANY PROFILE
27.1 TEVA PHARMACEUTICALS USA, INC.
27.1.1 COMPANY OVERVIEW
27.1.2 REVENUE ANALYSIS
27.1.3 GEOGRAPHIC PRESENCE
27.1.4 PRODUCT PORTFOLIO
27.1.5 RECENT DEVELOPMENTS
27.2 WEEFSELPHARMA.COM
27.2.1 COMPANY OVERVIEW
27.2.2 REVENUE ANALYSIS
27.2.3 GEOGRAPHIC PRESENCE
27.2.4 PRODUCT PORTFOLIO
27.2.5 RECENT DEVELOPMENTS
27.3 ADVACARE PHARMA
27.3.1 COMPANY OVERVIEW
27.3.2 REVENUE ANALYSIS
27.3.3 GEOGRAPHIC PRESENCE
27.3.4 PRODUCT PORTFOLIO
27.3.5 RECENT DEVELOPMENTS
27.4 NOVARTIS AG
27.4.1 COMPANY OVERVIEW
27.4.2 REVENUE ANALYSIS
27.4.3 GEOGRAPHIC PRESENCE
27.4.4 PRODUCT PORTFOLIO
27.4.5 RECENT DEVELOPMENTS
27.5 DR. REDDY’S LABORATORIES, INC.
27.5.1 COMPANY OVERVIEW
27.5.2 REVENUE ANALYSIS
27.5.3 GEOGRAPHIC PRESENCE
27.5.4 PRODUCT PORTFOLIO
27.5.5 RECENT DEVELOPMENTS
27.6 APOTEX INC.
27.6.1 COMPANY OVERVIEW
27.6.2 REVENUE ANALYSIS
27.6.3 GEOGRAPHIC PRESENCE
27.6.4 PRODUCT PORTFOLIO
27.6.5 RECENT DEVELOPMENTS
27.7 STRIDES PHARMA SCIENCE LIMITED
27.7.1 COMPANY OVERVIEW
27.7.2 REVENUE ANALYSIS
27.7.3 GEOGRAPHIC PRESENCE
27.7.4 PRODUCT PORTFOLIO
27.7.5 RECENT DEVELOPMENTS
27.8 ASTELLAS PHARMA US, INC.
27.8.1 COMPANY OVERVIEW
27.8.2 REVENUE ANALYSIS
27.8.3 GEOGRAPHIC PRESENCE
27.8.4 PRODUCT PORTFOLIO
27.8.5 RECENT DEVELOPMENTS
27.9 ACCORD HEALTHCARE US
27.9.1 COMPANY OVERVIEW
27.9.2 REVENUE ANALYSIS
27.9.3 GEOGRAPHIC PRESENCE
27.9.4 PRODUCT PORTFOLIO
27.9.5 RECENT DEVELOPMENTS
27.1 BIOCON
27.10.1 COMPANY OVERVIEW
27.10.2 REVENUE ANALYSIS
27.10.3 GEOGRAPHIC PRESENCE
27.10.4 PRODUCT PORTFOLIO
27.10.5 RECENT DEVELOPMENTS
27.11 GLENMARK PHARMACEUTICALS U.S. INC.
27.11.1 COMPANY OVERVIEW
27.11.2 REVENUE ANALYSIS
27.11.3 GEOGRAPHIC PRESENCE
27.11.4 PRODUCT PORTFOLIO
27.11.5 RECENT DEVELOPMENTS
27.12 TAJ PHARMA GROUP
27.12.1 COMPANY OVERVIEW
27.12.2 REVENUE ANALYSIS
27.12.3 GEOGRAPHIC PRESENCE
27.12.4 PRODUCT PORTFOLIO
27.12.5 RECENT DEVELOPMENTS
27.13 ALKEM
27.13.1 COMPANY OVERVIEW
27.13.2 REVENUE ANALYSIS
27.13.3 GEOGRAPHIC PRESENCE
27.13.4 PRODUCT PORTFOLIO
27.13.5 RECENT DEVELOPMENTS
27.14 CONCORD BIOTECH
27.14.1 COMPANY OVERVIEW
27.14.2 REVENUE ANALYSIS
27.14.3 GEOGRAPHIC PRESENCE
27.14.4 PRODUCT PORTFOLIO
27.14.5 RECENT DEVELOPMENTS
27.15 PANACEA BIOTEC
27.15.1 COMPANY OVERVIEW
27.15.2 REVENUE ANALYSIS
27.15.3 GEOGRAPHIC PRESENCE
27.15.4 PRODUCT PORTFOLIO
27.15.5 RECENT DEVELOPMENTS
27.16 MYLAN N.V.
27.16.1 COMPANY OVERVIEW
27.16.2 REVENUE ANALYSIS
27.16.3 GEOGRAPHIC PRESENCE
27.16.4 PRODUCT PORTFOLIO
27.16.5 RECENT DEVELOPMENTS
27.17 NIKSAN PHARMACEUTICAL
27.17.1 COMPANY OVERVIEW
27.17.2 REVENUE ANALYSIS
27.17.3 GEOGRAPHIC PRESENCE
27.17.4 PRODUCT PORTFOLIO
27.17.5 RECENT DEVELOPMENTS
27.18 WELLONA PHARMA
27.18.1 COMPANY OVERVIEW
27.18.2 REVENUE ANALYSIS
27.18.3 GEOGRAPHIC PRESENCE
27.18.4 PRODUCT PORTFOLIO
27.18.5 RECENT DEVELOPMENTS
27.19 SANOFI
27.19.1 COMPANY OVERVIEW
27.19.2 REVENUE ANALYSIS
27.19.3 GEOGRAPHIC PRESENCE
27.19.4 PRODUCT PORTFOLIO
27.19.5 RECENT DEVELOPMENTS
27.2 LUPIN PHARMACEUTICALS, INC.
27.20.1 COMPANY OVERVIEW
27.20.2 REVENUE ANALYSIS
27.20.3 GEOGRAPHIC PRESENCE
27.20.4 PRODUCT PORTFOLIO
27.20.5 RECENT DEVELOPMENTS
27.21 OPELLA HEALTHCARE INTERNATIONAL SAS
27.21.1 COMPANY OVERVIEW
27.21.2 REVENUE ANALYSIS
27.21.3 GEOGRAPHIC PRESENCE
27.21.4 PRODUCT PORTFOLIO
27.21.5 RECENT DEVELOPMENTS
27.22 HEALTHY LIFE PHARMA PRIVATE LIMITED
27.22.1 COMPANY OVERVIEW
27.22.2 REVENUE ANALYSIS
27.22.3 GEOGRAPHIC PRESENCE
27.22.4 PRODUCT PORTFOLIO
27.22.5 RECENT DEVELOPMENTS
27.23 ZYDUS PHARMACEUTICALS, INC.
27.23.1 COMPANY OVERVIEW
27.23.2 REVENUE ANALYSIS
27.23.3 GEOGRAPHIC PRESENCE
27.23.4 PRODUCT PORTFOLIO
27.23.5 RECENT DEVELOPMENTS
27.24 AMNEAL PHARMACEUTICALS LLC
27.24.1 COMPANY OVERVIEW
27.24.2 REVENUE ANALYSIS
27.24.3 GEOGRAPHIC PRESENCE
27.24.4 PRODUCT PORTFOLIO
27.24.5 RECENT DEVELOPMENTS
27.25 AADI BIOSCIENCE, INC.
27.25.1 COMPANY OVERVIEW
27.25.2 REVENUE ANALYSIS
27.25.3 GEOGRAPHIC PRESENCE
27.25.4 PRODUCT PORTFOLIO
27.25.5 RECENT DEVELOPMENTS
27.26 PRESERVATION SOLUTION INC
27.26.1 COMPANY OVERVIEW
27.26.2 REVENUE ANALYSIS
27.26.3 GEOGRAPHIC PRESENCE
27.26.4 PRODUCT PORTFOLIO
27.26.5 RECENT DEVELOPMENTS
27.27 ORGAN PRESERVATION SOLUTION
27.27.1 COMPANY OVERVIEW
27.27.2 REVENUE ANALYSIS
27.27.3 GEOGRAPHIC PRESENCE
27.27.4 PRODUCT PORTFOLIO
27.27.5 RECENT DEVELOPMENTS
27.28 ORGANOX
27.28.1 COMPANY OVERVIEW
27.28.2 REVENUE ANALYSIS
27.28.3 GEOGRAPHIC PRESENCE
27.28.4 PRODUCT PORTFOLIO
27.28.5 RECENT DEVELOPMENTS
27.29 OPSL GROUP
27.29.1 COMPANY OVERVIEW
27.29.2 REVENUE ANALYSIS
27.29.3 GEOGRAPHIC PRESENCE
27.29.4 PRODUCT PORTFOLIO
27.29.5 RECENT DEVELOPMENTS
27.3 XVIVO PERFUSION
27.30.1 COMPANY OVERVIEW
27.30.2 REVENUE ANALYSIS
27.30.3 GEOGRAPHIC PRESENCE
27.30.4 PRODUCT PORTFOLIO
27.30.5 RECENT DEVELOPMENTS
27.31 SANDOR
27.31.1 COMPANY OVERVIEW
27.31.2 REVENUE ANALYSIS
27.31.3 GEOGRAPHIC PRESENCE
27.31.4 PRODUCT PORTFOLIO
27.31.5 RECENT DEVELOPMENTS
27.32 PARAGONIX TECHNOLOGIES
27.32.1 COMPANY OVERVIEW
27.32.2 REVENUE ANALYSIS
27.32.3 GEOGRAPHIC PRESENCE
27.32.4 PRODUCT PORTFOLIO
27.32.5 RECENT DEVELOPMENTS
27.33 AOPO ORGANIZATION
27.33.1 COMPANY OVERVIEW
27.33.2 REVENUE ANALYSIS
27.33.3 GEOGRAPHIC PRESENCE
27.33.4 PRODUCT PORTFOLIO
27.33.5 RECENT DEVELOPMENTS
27.34 CARDIOLINK GROUP
27.34.1 COMPANY OVERVIEW
27.34.2 REVENUE ANALYSIS
27.34.3 GEOGRAPHIC PRESENCE
27.34.4 PRODUCT PORTFOLIO
27.34.5 RECENT DEVELOPMENTS
27.35 ESSENTIAL PHARMACEUTICALS LLC
27.35.1 COMPANY OVERVIEW
27.35.2 REVENUE ANALYSIS
27.35.3 GEOGRAPHIC PRESENCE
27.35.4 PRODUCT PORTFOLIO
27.35.5 RECENT DEVELOPMENTS
27.36 TRANSMEDICS
27.36.1 COMPANY OVERVIEW
27.36.2 REVENUE ANALYSIS
27.36.3 GEOGRAPHIC PRESENCE
27.36.4 PRODUCT PORTFOLIO
27.36.5 RECENT DEVELOPMENTS
27.37 SALF SPA
27.37.1 COMPANY OVERVIEW
27.37.2 REVENUE ANALYSIS
27.37.3 GEOGRAPHIC PRESENCE
27.37.4 PRODUCT PORTFOLIO
27.37.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
28 RELATED REPORTS
29 CONCLUSION
30 QUESTIONNAIRE
31 ABOUT DATA BRIDGE MARKET RESEARCH
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
